Baxter International Inc. (NYSE: BAX) has initiated voluntary recalls of two injectable products after particulate matter contamination was identified in both solutions.
The first recall involves two lots of 0.9% Sodium Chloride Injection, which were found to potentially contain fiberglass particles within the solution.
The affected product was distributed between 31 July 2026 and 3 August 2026 to healthcare providers and distributors across multiple US states, including Florida, Illinois, Indiana, Louisiana, Maryland, Missouri, North Carolina, and New Jersey.
Intravenous administration of a solution containing fiberglass particulate matter can cause blockage and clotting in blood vessels, cutting off blood flow to vital organs.
Such contamination can also lead to a life-threatening blood clot in the lungs, known as a pulmonary embolism, and may result in permanent organ damage or death in severe cases.
Baxter is also voluntarily recalling one lot of 70% Dextrose Injection, which was found to potentially contain stainless steel particles in the solution.
Beyond the risk of vessel blockage and pulmonary embolism, stainless steel particles may cause local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions in patients.
As of 25 August 2026, Baxter has not received any reports of adverse events related to either product recall.
Separately, Vitruvias Therapeutics Inc. is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg after testing confirmed the product could be superpotent.
The recalled product is Lot No. 504950, carrying NDC 69680-166-00, with an expiration date of 30 September 2026, affecting 3,655 units released and 1,955 units sold.
Consumption of superpotent thyroid tablets can cause hyperthyroidism, including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.
The patient populations considered at greater risk from superpotent thyroid medication include elderly individuals, pregnant women, and infants, particularly over extended periods of use.
Vitruvias Therapeutics is notifying wholesalers by email and phone to discontinue distribution and is arranging for the destruction of all recalled product units.
Patients currently taking Thyroid, USP from Lot 504950 are advised not to discontinue use without first contacting their healthcare provider for further guidance and a potential replacement prescription.
Vitruvias Therapeutics has also confirmed it has not received any reports of adverse events known to be connected to the recall at this time.